Connect Biopharma Holdings Limited (CNTB)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
CNTB's rademikibart Phase 2 Trials Continue with No Safety Issues
# 🧾 What This Document Is This is an SEC filing called an 8-K, which companies use to announce major news to investors. This specific filing includes a press release about a clinical trial update. It’s meant to keep the market informed about the progress of the company’s lead drug. 👉 **Why it mat
March 2026
Connect Biopharma Holdings Ltd — 8-K Filing
# 🧾 What This Document Is This is an **8-K filing**, which is like a major news alert a public company sends to the SEC and investors. This specific one includes a **press release** (the exhibit) where Connect Biopharma reports its 2025 financial results and gives a big update on its business prog
Connect Biopharma Holdings Ltd — 8-K Filing
# 🧾 What This Document Is This is a **Securities Purchase Agreement** filed as an exhibit to an 8-K report. Think of it as the detailed contract for a **private investment deal**. Connect Biopharma is selling new shares directly to a group of investors (not on the public stock market) to raise mone
SEC filings
All filings →Insider trades
All insider trades →Connect Biopharma Holdings Limited has no reported insider trades in the last 90 days.